Table 4 Control rate of spherical equivalent refractive error (SER) progression and axial length elongation on myopia children using atropine in different studies.
Author, year | Country | Study design | Age (y) | Baseline SER (D) | Follow-up time (M) | Change of SER (D) | Control rate of SER progression (%) | Change of axial length(mm) | Control rate of axial length elongation (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control group | Concentration of atropine | Control group | Concentration of atropine | ||||||||||||||||
Current study | Mainland China | RCT | 6–14 | − 1.25 to − 6.00 | 0.01% | 0.02% | 0.01% | 0.02% | 0.01% | 0.02% | 0.01% | 0.02% | |||||||
0 − 12 | − 0.70 | − 0.47 | − 0.38 | 32.9 | 45.7 | 0.46 | 0.37 | 0.30 | 19.6 | 34.8 | |||||||||
12 − 24 | − 0.63 | − 0.46 | − 0.42 | 27.0 | 33.3 | 0.42 | 0.35 | 0.32 | 16.7 | 23.8 | |||||||||
0 − 24 | − 1.33 | − 0.93 | − 0.80 | 30.1 | 39.8 | 0.88 | 0.72 | 0.62 | 18.2 | 29.5 | |||||||||
Chia et al.7 | Singapore | RCT | 6–12 | ≤ − 2.0 | 0.01% | 0.1% | 0.5% | 0.01% | 0.1% | 0.5% | 0.01% | 0.1% | 0.5% | 0.01% | 0.1% | 0.5% | |||
0–12 | − 0.76 | − 0.43 | − 0.31 | − 0.17 | 43.4 | 59.2 | 77.6 | 0.20 | 0.24 | 0.13 | 0.11 | 0 | 35.0 | 45.0 | |||||
12–24 | − 0.44 | − 0.06 | − 0.07 | − 0.13 | 86.4 | 84.1 | 70.5 | 0.18 | 0.17 | 0.15 | 0.16 | 5.6 | 16.7 | 11.1 | |||||
0–24 | − 1.20 | − 0.49 | − 0.38 | − 0.30 | 59.2 | 68.3 | 75 | 0.38 | 0.41 | 0.28 | 0.27 | 0 | 26.3 | 29.0 | |||||
Yam et al.11 | Hong Kong, China | RCT | 4–12 | ≤ − 1.0 | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | |||
0–12 | − 0.81 | − 0.64 | − 0.46 | − 0.25 | 21.0 | 43.2 | 69.1 | 0.41 | 0.35 | 0.29 | 0.20 | 14.6 | 29.3 | 51.2 | |||||
12–24 | – | − 0.48 | − 0.39 | − 0.30 | – | – | – | – | 0.25 | 0.22 | 0.18 | – | – | – | |||||
0–24 | – | − 1.12 | − 0.85 | − 0.55 | – | – | – | – | 0.59 | 0.50 | 0.39 | – | – | – | |||||
Larkin et al.12 | American | Retrospective | 6–15 | − 0.25to − 8.00 | 0.01% | 0.01% | |||||||||||||
0–12 | − 0.6 | − 0.2 | 66.7 | ||||||||||||||||
12–24 | − 0.6 | − 0.1 | 83.3 | ||||||||||||||||
0–24 | − 1.2 | − 0.3 | 75 | ||||||||||||||||
Wei et al.13 | Mainland China | RCT | 6–12 | − 1.00 to − 6.00 | 0.01% | 0.01% | 0.01% | 0.01% | |||||||||||
0–12 | − 0.76 | − 0.49 | 35.5 | 0.41 | 0.32 | 22.0 | |||||||||||||
Clark et al.14 | American | Retrospective | 6–15 | − 0.25to − 8.00 | 0.01 | 0.01% | |||||||||||||
0–12 | − 0.6 | − 0.1 | 83.3 | ||||||||||||||||
Moon et al.17 | Korea | Retrospective | 5–14 | ≥ − 6.0 | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | 0.01% | 0.025% | 0.05% | |||
0–12 | − 1.61 | − 0.84 | − 0.56 | − 0.23 | 47.8 | 65.2 | 85.7 | 0.55 | 0.44 | 0.30 | 0.23 | 20.0 | 45.5 | 58.2 | |||||
Joachimsen et al.16 | German | Retrospective | 6–17 | SE progression ≥ 0.5 D /year | 0.01% | 0.01% | |||||||||||||
0–12 M | − 1.05 | − 0.40 | 61.9 | ||||||||||||||||
Sacchi et al.15 | European | Retrospective | 5–14 | SE progression ≥ 0.5 D /year | 0.01% | 0.01% | |||||||||||||
0–12 M | − 1.09 | − 0.54 | 50.5 | ||||||||||||||||
